The concentration of LNT found in human milk varies, depending on maternal genetics and lactation stage. Typically, concentrations of LNT between 0.2 and 1.6 g/l are reported in mature human milk, with an average of 0.74 g/l¹. LNT is the most abundant representative of the category of neutral non-fucosylated HMOs.
Preclinical science has shown that LNT can stimulate the growth of infant-specific Bifidobacteria species in the gut microbiota². Furthermore, LNT has been shown to have some specific anti-pathogenic activity; it can inhibit growth and biofilm formation of group B streptococcus (Streptococcus agalactiae)³⁺⁴ and reduce attachment and infectivity of the parasite Entamoeba histolytica⁵. Aequival® LNT is structurally identical to the oligosaccharide LNT that is found in human milk. The product is a non-GMO ingredient produced with fermentation technology using lactose as a substrate. Currently, Aequival® LNT is in the final stages of development